Young children and the elderly risk being missed entirely
A disease that travels on the wings of mosquitoes does not distribute its suffering equally — and a sweeping review of 101 studies now makes clear that chikungunya speaks a different language to each stage of human life. Published in PLOS Neglected Tropical Diseases, the analysis finds that young children and the elderly bear the heaviest burden of death and hospitalization, while working-age adults are condemned to a slower suffering: chronic joint pain that can endure for years. As the virus extends its reach to more than three-quarters of the global population, the medical world is being asked to stop treating chikungunya as a single disease and start seeing it as many.
- Chikungunya now threatens over 75% of the world's population and cost nearly $50 billion in a single decade, yet medicine has largely treated it as one disease with one face.
- Young children under nine and the elderly face the sharpest risk of death — some studies report elderly mortality rates above 20% — while older children, paradoxically, recover faster than any other group.
- Because the WHO's diagnostic criteria center on fever and joint pain, children and elderly patients who present atypically are being missed or misdiagnosed at dangerous rates.
- Adults escape the worst acute outcomes but pay a long-term price: chronic joint pain, fatigue, and disability affect anywhere from 25% to 90% of adult patients and drain productivity for months or years.
- With two vaccines now approved, the urgency has shifted from whether to protect people to how — and this review makes the case that age-specific strategies are no longer optional.
Chikungunya is spreading faster and farther than ever, threatening more than three-quarters of the global population and costing nearly $50 billion in direct and indirect losses between 2011 and 2020. Yet a fundamental truth has gone underexamined: the disease does not strike everyone the same way. A new systematic review of 101 studies, published in PLOS Neglected Tropical Diseases, reveals that chikungunya follows distinctly different patterns depending on a patient's age — with serious consequences for how it is diagnosed, treated, and prevented.
Analyzing data from 133 study populations, researchers divided patients into three groups: children under 18, adults aged 18 to 64, and the elderly aged 65 and older. The results are stark. Young children and the elderly face the highest risk of severe disease and death — some studies report elderly mortality rates exceeding 20%. A child under nine carries a significantly elevated risk of dying compared to a young adult. Older children, by contrast, recover faster than any other group, suggesting a brief protective window between early childhood and adolescence.
How the disease announces itself also shifts with age. Fever appears in over 80% of adults and elderly patients but less frequently in children. Rash and headache are far more common in adolescents and adults. Most critically, joint pain — the virus's signature symptom and a cornerstone of WHO diagnostic criteria — is reported less often in children and the elderly. This creates a dangerous blind spot: patients who don't fit the textbook presentation risk being missed entirely.
Adults face a different burden. Though they generally survive the acute phase, a substantial share — between 25% and 90% depending on the study — develop chronic symptoms: persistent joint pain, fatigue, and reduced mobility lasting months or years. The economic toll on working-age populations is considerable, rippling through families and healthcare systems alike. Chronic disease risk also rises steadily with age, from roughly 17% in the youngest children to far higher rates in adults.
The researchers argue that current diagnostic tools, treatment protocols, and vaccination strategies have been built without adequately accounting for these age-related differences. With two chikungunya vaccines now approved, the question is no longer whether to act, but how to direct limited resources toward those who need protection most — and in forms they can actually benefit from.
Chikungunya is spreading faster and farther than ever. The mosquito-borne virus now threatens more than three-quarters of the global population, and the economic toll is staggering—nearly $50 billion in combined direct and indirect costs between 2011 and 2020 alone. Yet despite its reach, doctors and public health officials have struggled to understand a crucial fact: the disease does not hit everyone the same way. A new systematic review of 101 studies, published in PLOS Neglected Tropical Diseases, reveals that chikungunya manifests in distinctly different patterns depending on age, with profound implications for diagnosis, treatment, and prevention.
Researchers analyzed data from 133 study populations across three age groups: children under 18, adults aged 18 to 64, and the elderly aged 65 and older. The findings paint a clear picture of vulnerability. Young children and the elderly face the highest risk of severe disease—hospitalization and death occur most frequently in these two groups. A child under nine years old, for instance, faces a significantly elevated risk of death compared to a young adult. Similarly, the elderly show mortality rates that dwarf those in other age groups, with some studies reporting rates above 20 percent. Yet the story does not end with severity. Older children, by contrast, tend to recover faster than any other age group, suggesting that the window between early childhood and adolescence offers some protective advantage.
The way chikungunya announces itself also varies sharply by age. Fever, that hallmark symptom, appears in roughly 80 percent or more of adults and elderly patients but shows up in fewer than 80 percent of children. Rash and headache—symptoms that doctors rely on for diagnosis—occur far more often in adolescents and adults than in young children or the elderly. This discrepancy creates a dangerous blind spot. Joint pain, the signature complaint of chikungunya, is reported less frequently in children and the elderly than in adults. Because the World Health Organization's case definition emphasizes fever and joint pain as key diagnostic markers, patients in these age groups who lack these typical symptoms risk being misdiagnosed or missed entirely. The elderly, in particular, present with atypical disease patterns that can mask the true diagnosis.
Adults, while generally spared the worst acute outcomes, face a different burden. They experience arthralgia—joint pain—more often than any other age group, and a substantial portion develop chronic symptoms that persist for months or years. Among adults, chronic chikungunya symptoms appear in rates ranging from 25 to 90 percent, depending on the study. This chronic phase brings debilitating joint pain, fatigue, and reduced mobility that can last indefinitely. For working-age adults, the consequence is substantial: lost productivity, reduced quality of life, and long-term disability. The economic impact ripples outward through families and healthcare systems.
The pattern becomes clearer as age increases. Chronic symptoms become more likely with each passing year. A child aged zero to four years develops chronic disease at a rate of roughly 17 percent, while children aged ten to fifteen show rates approaching 24 percent. Adults exceed these figures substantially. The immune system's response to the virus appears to shift with age—infants and the very old mount weaker acute responses but paradoxically suffer worse outcomes, while the elderly's reduced immune capacity leaves them vulnerable to prolonged inflammation and tissue damage.
These findings underscore a critical gap in current medical practice. Diagnostic criteria, treatment protocols, and vaccination strategies have been designed largely without accounting for age-specific differences. The researchers emphasize that better age-specific healthcare strategies are essential. For young children and the elderly, this means developing diagnostic tools that account for atypical presentations. For adults, it means recognizing and managing the chronic phase aggressively to prevent long-term disability. And for all age groups, it means tailoring prevention efforts—including vaccination—to maximize protection where it is needed most. With two chikungunya vaccines now approved for use, understanding these age-related patterns becomes even more urgent. The question is no longer whether to vaccinate, but how to allocate limited resources to protect the most vulnerable while reducing the broader disease burden worldwide.
Notable Quotes
Young children and the elderly are at the highest risk for severe disease, such as hospitalization and death, while older children tend to recover faster than other age groups.— Study findings
Young children and the elderly were reported to experience joint pain less often, which could increase the chance of misdiagnosis.— Study findings
The Hearth Conversation Another angle on the story
Why does chikungunya hit the very young and very old so much harder than people in the middle?
It comes down to immunity. Infants haven't finished building their immune systems yet, and older adults have immune systems that have begun to decline. Both groups struggle to mount an effective early response to the virus. But here's the paradox: the elderly often develop worse long-term complications, suggesting their immune systems overreact or get stuck in a damaging cycle.
So if older children recover faster, does that mean they're naturally immune?
Not exactly. It's more that children between five and fifteen seem to hit a sweet spot—their immune systems are mature enough to fight the virus effectively but not yet prone to the chronic inflammation that plagues older adults. They clear the infection and move on. It's a narrow window.
The study mentions that joint pain shows up less often in children and the elderly. Isn't that a good thing?
It sounds like it should be, but it's actually dangerous. Doctors use joint pain as a key diagnostic clue. When it's absent, the disease gets missed or misdiagnosed as something else. A child might be treated for the wrong condition while chikungunya spreads unchecked. The elderly face the same problem, only worse because their atypical presentations are even more pronounced.
What about the chronic phase? Is that mainly an adult problem?
It's worse in adults, yes, but it's not confined to them. The data show that chronic symptoms increase with age across all groups. A child might have a 17 percent chance of chronic disease; an adult might have 50 percent or higher. The elderly don't have as much data, but what exists suggests they suffer chronic complications too—they're just less likely to report joint pain, so it goes unrecognized.
If we have vaccines now, how does this age-specific knowledge change vaccination strategy?
It changes everything. You can't use a one-size-fits-all approach. You need to prioritize infants and the very elderly for protection because they face the worst acute outcomes. But you also need to vaccinate working-age adults to prevent the chronic disability that costs economies billions in lost productivity. The real challenge is deciding where to start when resources are limited.